MRNA vs PCVX
MRNA: Moderna is an unprofitable mRNA vaccine and therapeutic company pivoting from peak COVID revenues with a diversified pipeline facing intense competition and declining sales. PCVX: Vaxcyte engineers next-generation bacterial vaccines using cell-free protein synthesis to create broader-spectrum, more immunogenic alternatives to existing vaccines.
Side-by-side fundamentals
| Metric | MRNA | PCVX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $58.07 | $56.00 | |
| Market cap as of 2026-07-23 | $22.9B | $8.1B | |
| PEG as of 2026-07-23 | n/a | -0.12 | |
| Net margin as of 2026-07-23 | -143.6% | n/a | |
| Gross margin as of 2026-07-23 | +35.0% | n/a | |
| Operating margin as of 2026-07-23 | -153.3% | n/a | |
| ROE as of 2026-07-23 | -36.7% | -32.5% | PCVX higher |
| ROA as of 2026-07-23 | -26.6% | -29.5% | MRNA higher |
| Debt / equity as of 2026-07-23 | 0.09 | 0.00 | PCVX lower |
| Revenue growth (YoY) as of 2026-07-23 | -30.0% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -53.4% | n/a | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-07-23 | 0.88 | 1.21 | |
| 1-year return as of 2026-07-22 close | +77.4% | +56.8% | MRNA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.